MDSpire - Takeaway
From the Journals

Can Shorter TB Prevention Regimens Work?

Randomized study evaluates efficacy, safety, and completion in high-risk patients

Share

  • 1

    Modified 3-month rifapentine plus isoniazid regimen noninferior to 9-month regimen.

  • 2

    Study involved 536 patients aged 18-70 with rheumatic diseases.

  • 3

    TB incidence: 0% in 3HP-PUMCH vs 1.2% in 9H group.

  • 4

    Adverse drug reactions: 9.6% in 3HP-PUMCH vs 15% in 9H.

  • 5

    Hepatotoxicity rates: 4.4% vs 10.4%.

  • 6

    Treatment completion: 89.6% for 3HP-PUMCH.

  • 7

    Need for larger trials noted to confirm findings.

  • 8

    Findings could influence clinical practice and policies on TB prevention.

Original Source(s)

Can Shorter TB Prevention Regimens Work?

  • by Julia Cipriano, MS, CMPP

  • March 23, 2026

Related Content

Lyme Vaccine Advances in Late Trial

Large global study evaluates novel prevention strategy.

Why Copilots Failed in R&D and What Comes Next 

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.